STOCK TITAN

[6-K] Biophytis SA American Depositary Share (0.01 Euro) Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K
Rhea-AI Filing Summary

Biophytis S.A. (ticker: BPTS) filed a Form 6-K on June 24, 2025, to alert investors that, on June 19, 2025, it issued a press release announcing the temporary suspension of trading of its shares. The filing attaches the press release as Exhibit 99.1. No further details—such as the duration, cause, or expected resolution of the suspension—are provided in the submission. The only signatory is Chairman and CEO Stanislas Veillet. Because the document offers no financial statements, earnings data, or transaction details, its sole material disclosure is the trading halt.

Biophytis S.A. (simbolo: BPTS) ha presentato un modulo 6-K il 24 giugno 2025 per informare gli investitori che, il 19 giugno 2025, ha diffuso un comunicato stampa annunciando la sospensione temporanea della negoziazione delle sue azioni. Alla comunicazione è allegato il comunicato stampa come Esibizione 99.1. Non vengono forniti ulteriori dettagli, come la durata, la causa o la possibile risoluzione della sospensione. L'unico firmatario è il Presidente e CEO Stanislas Veillet. Poiché il documento non contiene bilanci, dati sugli utili o dettagli sulle transazioni, l'unica informazione rilevante è la sospensione delle negoziazioni.

Biophytis S.A. (símbolo bursátil: BPTS) presentó un Formulario 6-K el 24 de junio de 2025 para alertar a los inversores que, el 19 de junio de 2025, emitió un comunicado de prensa anunciando la suspensión temporal de la negociación de sus acciones. El archivo adjunta el comunicado como Anexo 99.1. No se proporcionan más detalles, como la duración, la causa o la resolución esperada de la suspensión. El único firmante es el presidente y CEO Stanislas Veillet. Dado que el documento no ofrece estados financieros, datos de ganancias ni detalles de transacciones, la única divulgación relevante es la suspensión de la negociación.

Biophytis S.A. (티커: BPTS)는 2025년 6월 24일 Form 6-K를 제출하여 투자자들에게 2025년 6월 19일 자로 자사 주식의 일시적 거래 중단을 발표하는 보도자료를 발행했음을 알렸습니다. 제출서류에는 보도자료가 Exhibit 99.1로 첨부되어 있습니다. 중단의 기간, 원인 또는 예상 해결 방안과 같은 추가 정보는 제공되지 않았습니다. 서명자는 회장 겸 CEO인 Stanislas Veillet 한 명뿐입니다. 이 문서에는 재무제표, 수익 데이터 또는 거래 내역이 포함되어 있지 않아, 유일한 중요한 공시는 거래 중단입니다.

Biophytis S.A. (symbole : BPTS) a déposé un formulaire 6-K le 24 juin 2025 pour informer les investisseurs qu’elle a publié un communiqué de presse le 19 juin 2025 annonçant la suspension temporaire de la négociation de ses actions. Le dépôt inclut le communiqué en tant qu’Exhibit 99.1. Aucun détail supplémentaire — tel que la durée, la cause ou la résolution attendue de la suspension — n’est fourni. Le seul signataire est le président-directeur général Stanislas Veillet. Étant donné que le document ne contient ni états financiers, ni données de résultats, ni détails de transactions, la seule information importante est l’arrêt de la négociation.

Biophytis S.A. (Ticker: BPTS) reichte am 24. Juni 2025 ein Formular 6-K ein, um Investoren darüber zu informieren, dass am 19. Juni 2025 eine Pressemitteilung veröffentlicht wurde, in der die vorübergehende Aussetzung des Handels mit ihren Aktien angekündigt wurde. Die Einreichung enthält die Pressemitteilung als Anlage 99.1. Weitere Details wie Dauer, Ursache oder erwartete Beendigung der Aussetzung werden nicht angegeben. Der einzige Unterzeichner ist Vorstandsvorsitzender und CEO Stanislas Veillet. Da das Dokument keine Finanzberichte, Gewinnzahlen oder Transaktionsdetails enthält, ist die einzige wesentliche Information der Handelsstopp.

Positive
  • None.
Negative
  • Temporary suspension of share trading announced with no accompanying explanation, increasing uncertainty and potential downside risk for current and prospective investors.

Insights

TL;DR (25 words): Trading suspension notice; lack of context heightens uncertainty; negative market signal until clarified.

The filing is limited to informing the market that Biophytis shares are temporarily suspended from trading, with no explanation offered. A trading halt generally signals potential regulatory, liquidity, or corporate issues, all of which can pressure valuation. Investors have no timeline for resumption, nor insight into underlying causes, impeding risk assessment and potentially elevating volatility once trading reopens.

TL;DR (22 words): Suspension increases operational and liquidity risk; disclosure gap compounds uncertainty and could affect investor confidence.

From a risk perspective, an unclarified trading halt is a red flag. The absence of explanatory detail limits stakeholders’ ability to gauge legal, compliance, or solvency implications. Until management provides additional information, counterparty and financing risks may rise, and institutional holders could reassess exposure. The situation is materially negative unless resolved promptly with transparent communication.

Biophytis S.A. (simbolo: BPTS) ha presentato un modulo 6-K il 24 giugno 2025 per informare gli investitori che, il 19 giugno 2025, ha diffuso un comunicato stampa annunciando la sospensione temporanea della negoziazione delle sue azioni. Alla comunicazione è allegato il comunicato stampa come Esibizione 99.1. Non vengono forniti ulteriori dettagli, come la durata, la causa o la possibile risoluzione della sospensione. L'unico firmatario è il Presidente e CEO Stanislas Veillet. Poiché il documento non contiene bilanci, dati sugli utili o dettagli sulle transazioni, l'unica informazione rilevante è la sospensione delle negoziazioni.

Biophytis S.A. (símbolo bursátil: BPTS) presentó un Formulario 6-K el 24 de junio de 2025 para alertar a los inversores que, el 19 de junio de 2025, emitió un comunicado de prensa anunciando la suspensión temporal de la negociación de sus acciones. El archivo adjunta el comunicado como Anexo 99.1. No se proporcionan más detalles, como la duración, la causa o la resolución esperada de la suspensión. El único firmante es el presidente y CEO Stanislas Veillet. Dado que el documento no ofrece estados financieros, datos de ganancias ni detalles de transacciones, la única divulgación relevante es la suspensión de la negociación.

Biophytis S.A. (티커: BPTS)는 2025년 6월 24일 Form 6-K를 제출하여 투자자들에게 2025년 6월 19일 자로 자사 주식의 일시적 거래 중단을 발표하는 보도자료를 발행했음을 알렸습니다. 제출서류에는 보도자료가 Exhibit 99.1로 첨부되어 있습니다. 중단의 기간, 원인 또는 예상 해결 방안과 같은 추가 정보는 제공되지 않았습니다. 서명자는 회장 겸 CEO인 Stanislas Veillet 한 명뿐입니다. 이 문서에는 재무제표, 수익 데이터 또는 거래 내역이 포함되어 있지 않아, 유일한 중요한 공시는 거래 중단입니다.

Biophytis S.A. (symbole : BPTS) a déposé un formulaire 6-K le 24 juin 2025 pour informer les investisseurs qu’elle a publié un communiqué de presse le 19 juin 2025 annonçant la suspension temporaire de la négociation de ses actions. Le dépôt inclut le communiqué en tant qu’Exhibit 99.1. Aucun détail supplémentaire — tel que la durée, la cause ou la résolution attendue de la suspension — n’est fourni. Le seul signataire est le président-directeur général Stanislas Veillet. Étant donné que le document ne contient ni états financiers, ni données de résultats, ni détails de transactions, la seule information importante est l’arrêt de la négociation.

Biophytis S.A. (Ticker: BPTS) reichte am 24. Juni 2025 ein Formular 6-K ein, um Investoren darüber zu informieren, dass am 19. Juni 2025 eine Pressemitteilung veröffentlicht wurde, in der die vorübergehende Aussetzung des Handels mit ihren Aktien angekündigt wurde. Die Einreichung enthält die Pressemitteilung als Anlage 99.1. Weitere Details wie Dauer, Ursache oder erwartete Beendigung der Aussetzung werden nicht angegeben. Der einzige Unterzeichner ist Vorstandsvorsitzender und CEO Stanislas Veillet. Da das Dokument keine Finanzberichte, Gewinnzahlen oder Transaktionsdetails enthält, ist die einzige wesentliche Information der Handelsstopp.

 

 

UNITED STATES SECURITIES

AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

Date of report: June 24, 2025

 

Commission File Number: 001-38974

 

BIOPHYTIS S.A.

(Translation of registrant’s name into English)

 

 

Stanislas Veillet
Biophytis S.A.

Sorbonne University—BC 9, Bâtiment A 4ème étage

4 place Jussieu

75005 Paris, France

+33 1 44 27 23 00

(Address of principal executive office)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

x Form 20-F  ¨  Form 40-F

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

 

 

 

 

 

 

On June 19, 2025, Biophytis S.A. issued a press release announcing the temporary suspension of the trading of its shares .A copy of the press release is attached as Exhibit 99.1 to this Form 6-K.

 

EXHIBIT LIST

 

Exhibit   Description
99.1   Press Release dated January 19, 2025.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  BIOPHYTIS S.A.
     
Date: June 24, 2025 By: /s/ Stanislas Veillet
    Name: Stanislas Veillet
    Title: Chairman and Chief Executive Officer

 

 

 

FAQ

What did Biophytis S.A. (BPTS) disclose in its June 24, 2025 Form 6-K?

The company reported that it issued a press release on June 19, 2025 announcing a temporary suspension of trading of its shares.

Is the reason for Biophytis' trading suspension stated in the filing?

No. The Form 6-K provides no details regarding the cause or expected duration of the suspension.

Where can investors find the full press release about the suspension?

The press release is attached to the Form 6-K as Exhibit 99.1.

Who signed the Biophytis Form 6-K dated June 24, 2025?

The document was signed by Stanislas Veillet, Chairman and Chief Executive Officer.

Does the filing include any financial results or earnings data?

No financial statements or earnings figures are included; the filing solely discloses the trading suspension.
Biophytis SA American Depositary Share (0.01 Euro)

NASDAQ:BPTS

BPTS Rankings

BPTS Latest News

BPTS Stock Data

2.36M
1.40B
0.05%
3.22%
Biotechnology
Healthcare
Link
France
Paris